Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer

Clinical Lung Cancer

Volumn 10, Issue 1, 2009, Pages 58-66

  Khoury, Thaer ^a   Alrawi, Sadir ^b   Ramnath, Nithva ^a   Li, Qiang ^a   Grimm, Melissa ^a   Black, Jennifer ^a   Tan, Dongfeng ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytokeratin 7; Immunohistochemistry; mRNA; Western blot

Indexed keywords

CYCLIN D1; INITIATION FACTOR 4E;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 62549083454     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.009     Document Type: Article

References (44)

1. Mamane Y, Petroulakis E, Rong L, et al. eIF4E from translation to transformation. Oncogene 2004; 23:3172-9.
2. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Ann Rev Biochem 1999; 68:913-63.
3. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999; 31:59-72.
4. Rosenwald IB, Kaspar R, Rosseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995; 270:21176-80.
5. Lai HK, Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene 2000;19:1623-34.
6. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, et al. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993; 13:7358-63.
7. Colby TV, Noguchi M, Henschke C. Tumors of the lung. In: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004:10-124.
8. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-7.
9. Ramnath N, Hernandez F, Tan DF, et al. Mcm-2 is an independent predictor of survival in patients with non-small cell lung cancer. J Clin Oncol 2001; 19:4259-66.
10. Rosenwald IB, Hutzler MJ, Wang S, et al. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001; 92:2164-71.
11. Seki N, Takasu T, Mandai K, et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002; 8:3046-53.
12. Walsh D, Meleady P, Power B, et al. Increased levels of the translation initiation factor eIF4E in differentiating epithelial lung tumor cell lines. Differentiation 2003; 71:126-34.
13. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23:3189-99.
14. Pelletier J, Sonenberg N. The involvement of mRNA secondary structure in protein synthesis. Biochem Cell Biol 1987; 65:576-81.
15. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 1991; 115:887-903.
16. Thach RE. Cap recap: the involvement of eIF-4F in regulating gene expression. Cell 1992; 68:177-80.
17. Rhoads RE. Regulation of eukaryotic protein synthesis by initiation factors. J Biol Chem 1993; 268:3017-20.
18. Geballe AP, Morris DR. Initiation codons within 5′-leaders of mRNAs as regulators of translation. Trends Biochem Sci 1994; 19:159-64.
19. Morley SJ. Signal transduction mechanisms in the regulation of protein synthesis. Mol Biol Rep 1994; 19:221-31.
20. Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20:1343-51.
21. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003; 20:265-73.
22. Comtesse N, Keller A, Diesinger I, et al. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer 2007; 120:2538-44.
23. Yang SX, Hewitt SM, Steinberg SM, et al. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 2007;17:281-7.
24. Gygi SP, Rochon Y, Robert BF, et al. Correlation between Protein and mRNA Abundance in Yeast. Molec Cellular Biol 1999; 19:1720-30.
25. Hsieh CC, Chow KC, Fahn HJ, et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998; 66:1159-63.
26. Keum JS, Kong G, Yang SC, et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer 1999; 81:127-32.
27. Caputi M, Groeger AM, Esposito V, et al. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol 1999; 20:746-50.
28. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 34:207-18.
29. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005; 11:232-41.
30. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3:1051-8.
31. Anton RC, Coffey DM, Gondo MM, et al. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung. Mod Pathol 2000; 13:1167-72.
32. Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb, p16 (INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188:351-60.
33. Saitoh G, Sugio K, Ishida T, et al. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Rep 2001; 8:737-43.
34. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 2000; 82:1747-54.
35. Dworakowska D, Jassem E, Jassem J, et al. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21 (WAF1/CIP1) protein expression. J Cancer Res Clin Oncol 2005; 131:617-23.
36. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204:101-9.
37. Gautschi O, Hugli B, Ziegler A, et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006; 51:303-11.
38. Rousseau D, Kaspar R, Rosenwald I, et al. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 1996; 93:1065-70.
39. Lai HK, Borden KL. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA. Oncogene 2000; 19:1623-34.
40. Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 2003; 23:8992-9002.
41. Kentsis A, Topisirovic I, Culjkovic B, et al. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 2004; 101:18105-10.
42. Moerke NJ, Aktas H, Chen H, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128:257-67.
43. Bordeleau ME, Matthews J, Wojnar JM, et al. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci USA 2005; 102:10460-5.
44. Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001; 21:5500-11.